Research news

Research news

15 June 2019

The Nebido® Treatment Tracker is a tool designed to help HCPs improve patient adherence to Nebido treatment. The British Society for Sexual Medicine (BSSM) guideline recommends initiating testosterone therapy only in conjunction with weight-loss advice and lifestyle modification.  Considering that lifestyle change is notoriously difficult for patients to achieve and maintain, and the need for long-term adherence to Nebido® treatment in order to achieve the full spectrum of health benefits, the Nebido® Treatment Tracker was developed.

Read article
16 May 2019

Type 2 diabetes is a costly disease that is highly prevalent among men with hypogonadism. Unless given testosterone therapy, these men often struggle to achieve glycemic targets.

Many studies have shown that testosterone therapy increases insulin sensitivity and reduces HbA1c. These improvements in glycemic control are particularly after long-term testosterone therapy lasting for at least 6 years. This suggests that there may be a chance to prevent type 2 diabetes with testosterone therapy in men with hypogonadism.

Read article
15 May 2019

Is it possible to stop or delay the onset of diabetes in hypogonadal men with testosterone therapy?

The “Testosterone 4 Diabetes Mellitus” study, also known as the T4DM trial, is a randomised, double-blind, placebo-controlled trial – the gold standard study method - designed to find out if testosterone therapy with Nebido®/Reandron® combined with lifestyle intervention (Weight Watchers®) for 2 years versus lifestyle intervention alone, improves glucose tolerance and reduces incidence of type 2 diabetes.

The T4DM trial will be the first ever RCT to specifically investigate the effects of testosterone therapy on motivation / behaviour and telomere length, a biomarker of aging.

Read article
15 February 2019

A prerequisite for successful testosterone therapy is that the therapeutic testosterone target level of 15-30 nmol/mL is maintained long-term in order for symptom resolution and health benefits to occur. Therefore, adherence to testosterone therapy is critical.

New data showing superior adherence to testosterone therapy with long-acting testosterone undecanoate suggest that treatment with Nebido is more likely to confer long-term treatment benefits compared to gels and shot-acting testosterone preparations.

Read article
15 January 2019

Due to a high prevalence of hypogonadism in type 2 diabetic men, current guidelines recommend to test for low levels of testosterone in diabetic men.

A progressive reduction in waist circumference, along with a progressive improvement in erectile function as well as markedly reduces need for diabetes medications was shown in a 4-year follow-up analysis of the BLAST study in men with hypogonadism and type 2 diabetes who stay on long-term testosterone therapy with testosterone undecanoate.

Read article
15 December 2018

Does it matter which testosterone preparation is prescribed for testosterone therapy? This is a common question among HCPs as well as patients. A new meta-analysis shows that testosterone therapy with injectable testosterone preparations results in larger muscle and strength gains compared to transdermal testosterone preparations. This has important implications for the growing population of men with hypogonadism, who are at high risk of lean (muscle) mass loss, obesity, diabetes and sarcopenia.

    Read article
    23 November 2018

    The Testosterone Trials show that testosterone therapy confers significant and clinically meaningful health benefits in older men with low testosterone levels. Even though the Testosterone Trials aimed to recruit men with hypogonadism due to no apparent reason other than age, in fact the majority of enrolled men were obese and more than one third had type 2 diabetes. Obesity, metabolic syndrome and/or type 2 diabetes are stronger risk factors for hypogonadism than aging per se. Consequently, the Testosterone Trials provide compelling evidence that testosterone therapy confers significant benefits in the growing population of men with obesity and/or type 2 diabetes.

    Read article
    15 October 2018

    A new study was recently published in The Aging Male which treated hypogonadal patients with type 2 diabetes who had recently suffered a stroke with testosterone undecanoate. During the acute phase of stroke, patients received standard treatment with reperfusion, anti-hypertensives and anti-coagulants etc. but testosterone was started as soon as 1 week later.

    After 5 years of testosterone undecanoate treatment, there was a marked reduction of incident stroke and mortality. More patients receiving testosterone were able to return to work, compared to the untreated control group. The increased survival seen after 5 years of testosterone undecanoate treatment is accompanied by:

    Read article
    15 September 2018

    A long-held belief is that high testosterone levels increase risk of prostate cancer. To the contrary, most studies show that it is low testosterone that increases risk of prostate cancer. Furthermore, emerging data – summarized here - suggest that it may not be the absolute level of testosterone that predicts prostate cancer development, but rather patterns of change in testosterone levels, such as steep declines with age or reductions in testosterone at younger age. Maintaining stable testosterone levels throughout lifespan with testosterone therapy may have a significant impact on prostate cancer prevention.

    Read article
    15 August 2018

    Hypogonadism (testosterone deficiency) is more common than previously thought, even in younger men. Men with hypogonadism – regardless of age – have a higher prevalence of muscle weakness and simultaneous occurrence of several risk factors and chronic diseases.

    Considering the strong association between low testosterone and multimorbidity even in young men, it is possible that low testosterone may play a causal role in chronic disease development, such as obesity, metabolic syndrome, cardiovascular disease and type 2 diabetes, the prevalence of which has reached epidemic proportions over the last decade. Early detection and treatment of low testosterone, particularly in younger men, could possibly slow progression, or potentially stop disease development entirely.

     

    Read article
    • PP-NEB-ALL-0347-1

    Copyright © 2019,
    Bayer AG

    This website is intended to provide information to an international audience outside the USA and UK.

    Page last modified Mon, 16/09/2019

    Bayer logo